High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial
CONCLUSIONS: This study found negligible bactericidal activity of high-dose isoniazid (15-20 mg/kg) in the majority of participants with tuberculosis caused by katG-mutated M.tb. Clinical trial registration available at www.CLINICALTRIALS: gov, ID: NCT01936831.PMID:38564365 | DOI:10.1164/rccm.202311-2004OC
Source: Respiratory Care - Category: Respiratory Medicine Authors: Kamunkhwala Gausi Elisa H Ignatius Veronique De Jager Caryn Upton Soyeon Kim Ashley McKhann Laura Moran Lubbe Wiesner Florian von Groote-Bidlingmaier Philip Marzinek Naadira Vanker Joseph Yvetot Samuel Pierre Susan L Rosenkranz Susan Swindells Andreas H D Source Type: research